Stammdaten
Vertex Pharmaceuticals Inc. ist ein globales Biotechnologieunternehmen mit Schwerpunkt auf spezialisierten Märkten für schwere Erkrankungen. Das Unternehmen entwickelt und vermarktet Medikamente zur Behandlung von zystischer Fibrose (CF), Sichelzellenanämie (SCD) und transfusionsabhängiger Beta-Thalassämie (TDT). Zu den wichtigsten Produkten gehören ALYFTREK, TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI, KALYDECO für CF sowie CASGEVY für SCD und TDT. JOURNAVX ist ein zugelassenes Medikament zur Behandlung von akuten Schmerzen bei Erwachsenen. Vertex investiert stark in Forschung und Entwicklung, mit einem Fokus auf IgA-Nephropathie (IgAN), APOL1-vermittelte Nierenerkrankung (AMKD), neuropathischen Schmerz, Typ-1-Diabetes (T1D) und andere schwere Krankheiten. Das Unternehmen verfolgt einen seriellem Innovationsansatz, um transformative Medikamente für Patienten bereitzustellen. Vertex hat mehrere klinische Studien in verschiedenen Phasen, darunter Phase 3-Studien zu IgAN mit povetacicept und neuropathischem Schmerz mit suzetrigine. Die Produkte werden weltweit über spezialisierte Apotheken, Großhändler und direkte Vertriebsvereinbarungen vertrieben. Das Unternehmen arbeitet eng mit Gesundheitsdienstleistern, Krankenhäusern und Versicherern zusammen, um den Zugang zu seinen Therapien zu erleichtern. Vertex beschäftigt sich auch mit der Entwicklung von genetischen Therapien und anderen innovativen Ansätzen zur Behandlung von CF, SCD und TDT. KI
Unternehmen & Branche
| Name | VERTEX PHARMACEUTICALS INC / MA |
|---|---|
| Ticker | VRTX |
| CIK | 0000875320 |
| Börse | Nasdaq |
| Sektor | Gesundheit |
| Industrie | Pharmazeutische Erzeugnisse |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 92532F100 |
|---|---|
| ISIN | US92532F1003 |
| Typ | Common Stock |
| Marktkapitalisierung | 121,25 Mrd. USD |
| KGV (P/E) | 31,16 |
| Beta | 0,29 |
Sitz & Kontakt
| Sitz (Inkorporation) | MA |
|---|---|
| Geschäftsadresse | 50 NORTHERN AVENUE, 02210 BOSTON, MA |
| Telefon | 6173416393 |
| EIN (IRS) | 04-3039129 |
Listing & Historie
| Listing-Börsen | Nasdaq |
|---|---|
| Fiskaljahr-Ende | 31.12. |
| SEC-Filer-Status | Large accelerated filer |
Bewertung
| KBV (P/B) | 6,50 vs. 5,53 (2021) ▲ |
|---|---|
| KUV (P/S) | 10,10 vs. 7,38 (2021) ▲ |
| EV/EBITDA | 27,0 vs. 17,2 (2021) ▲ |
| FCF-Rendite | 2,6 % vs. 4,3 % (2021) ▼ |
| Buyback-Rendite | 1,7 % vs. 2,6 % (2021) ▼ |
Qualität & Bilanz
| Bruttomarge | 86,2 % vs. 88,1 % (2021) ▼ |
|---|---|
| Operative Marge | 34,8 % vs. 36,7 % (2021) ▼ |
| Nettomarge | 32,9 % vs. 30,9 % (2021) ▲ |
| ROIC | 19,1 % vs. 21,2 % (2021) ▼ |
| Nettoverschuldung/EBITDA | -0,7 vs. -2,0 (2021) ▲ |
| Zinsdeckungsgrad | 313,8 |
| Forderungslaufzeit (DSO) | 62 T vs. 55 T (2021) ▲ |
| Lagerreichweite (DIO) | 373 T vs. 143 T (2021) ▲ |
| Verbindlichkeitslaufzeit (DPO) | 102 T vs. 79 T (2021) ▲ |
| Cash-Conversion-Cycle (CCC) | 333 T vs. 119 T (2021) ▲ |
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | TTM* | Verlauf |
|---|---|---|---|---|---|---|---|
| Bewertung | |||||||
| KBV (P/B) | 5,53 | 5,33 | 5,96 | 6,31 | 6,17 | 6,26 | |
| KUV (P/S) | 7,38 | 8,31 | 10,62 | 9,39 | 9,59 | 9,92 | |
| EV/EBITDA | 17,2 | 14,5 | 23,7 | – | 25,6 | 24,0 | |
| FCF-Rendite | 4,3 % | 5,3 % | 3,2 % | -0,8 % | 2,8 % | 3,1 % | |
| Buyback-Rendite | 2,6 % | 0,0 % | 0,4 % | 1,1 % | 1,8 % | 1,6 % | |
| Qualität & Bilanz | |||||||
| Bruttomarge | 88,1 % | 87,9 % | 87,2 % | 86,1 % | 86,2 % | 86,2 % | |
| Operative Marge | 36,7 % | 48,2 % | 38,8 % | -2,1 % | 34,8 % | 38,3 % | |
| Nettomarge | 30,9 % | 37,2 % | 36,7 % | -4,9 % | 32,9 % | 35,5 % | |
| ROIC | 21,2 % | 22,4 % | 19,7 % | -2,9 % | 19,1 % | 20,3 % | |
| Nettoverschuldung/EBITDA | -2,0 | -2,2 | -2,4 | – | -0,7 | -0,7 | |
| Zinsdeckungsgrad | – | 78,6 | 86,9 | -7,6 | 313,8 | – | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
TTM* = letzte zwölf Monate (vorläufig, ungeprüft): jüngstes Geschäftsjahr + laufendes YTD − Vorjahres-YTD aus den Quartalsberichten (10-Q); Bewertungs-Multiples gegen die aktuelle Marktkapitalisierung. Kein testierter Jahresabschluss.
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Glück Conviction Score™ ⓘ
ⓘ
VRTX
VERTEX PHARMACEUTICALS INC / MA
Effektiv
Neutral
Handelsvolumen
Sehr hoch
Insider
0,0
Keine Insider-Käufe
Institutionell
39,6
146 neu, 673 erhöht, -6067487K $ netto
Aktivist
28,8
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,71% (Stand: 30.06.2026)
Score-Verlauf (90 Tage)
Konviktions-Verlauf — oben stark · Mitte neutral · unten schwach
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (24 Monate)
Indexierte Darstellung (Start = 100) — die Kursform bleibt sichtbar, absolute Kurse sind angemeldeten Mitgliedern vorbehalten.
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 464.82 | +3.1 % vs SMA50 | |
| Kurs vs SMA200 | Bullisch | 15 % | 451.53 | +6.1 % vs SMA200 | |
| SMA-Cross | Bullisch | 10 % | GOLDEN | vor 19 Tagen @ 499.65 | |
| EMA20 vs EMA50 | Bullisch | 5 % | 480.99 | EMA50: 470.70 | |
| MACD-Histogramm | Bärisch | 10 % | -3.472 | Bearisch | |
| RSI(14) | Neutral | 10 % | 50.1 | Neutral (30–70) | |
| Stoch %K(14) | Neutral | 5 % | 23.0 | Neutral | |
| ADX(14)+DI | Neutral | 10 % | 20.3 | +DI: 23.4 / −DI: 19.7 | |
| Z-Score(60) | Neutral | 5 % | 0.71 | In Range | |
| 52W-Position | Neutral | 5 % | 69.0 % | Hoch 529.59 / Tief 366.54 | |
| Bollinger(20,2σ) | Neutral | 5 % | 32.2 % | Upper 525.49 / Mid 491.22 / Lower 456.96 | |
| LinReg-Slope(60) | Bullisch | 10 % | +1.2859 | R²=0.65 / annualisiert +70.5 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-07-02 | McKechnie Duncan | Officer, EVP, Chief Commercial Officer | Open Market Sale | -1.541 | 519,00 | -799.779,00 | -48,2% | |
| 2026-07-02 | Tatsis Ourania | Officer, EVP, Chief Reg. & Quality Off. | Open Market Sale | -1.500 | 524,99 | -787.485,00 | -47,4% | |
| 2026-07-01 | Liu Joy | Officer, EVP and Chief Legal Officer | Open Market Sale | -828 | 502,71 | -416.243,88 | -25,1% | |
| 2026-06-26 | Bozic Carmen | Officer, EVP and CMO | Open Market Sale | -596 | 482,50 | -287.570,00 | -17,3% | |
| 2026-06-18 | Bozic Carmen | Officer, EVP and CMO | Open Market Sale | -1.020 | 462,17 | -471.413,40 | -28,4% | |
| 2026-06-15 | Bozic Carmen | Officer, EVP and CMO | Open Market Sale | -4.062 | 450,00 | -1.827.900,00 | -110,1% | |
| 2026-06-05 | Bozic Carmen | Officer, EVP and CMO | Open Market Sale | -1.745 | 450,00 | -785.250,00 | -47,3% | |
| 2026-06-01 | Liu Joy | Officer, EVP and Chief Legal Officer | Open Market Sale | -828 | 439,91 | -364.245,48 | -21,9% | |
| 2026-05-29 | Bozic Carmen | Officer, EVP and CMO | Open Market Sale | -1.974 | 450,00 | -888.300,00 | -53,5% | |
| 2026-05-15 | Bunnage Mark E. | Officer, EVP, Chief Scientific Officer | Open Market Sale | -33 | 453,45 | -14.963,85 | -0,9% | |
| 2026-05-15 | Bozic Carmen | Officer, EVP and CMO | Open Market Sale | -1.354 | 453,45 | -613.971,30 | -37,0% | |
| 2026-05-12 | Bozic Carmen | Officer, EVP and CMO | Open Market Sale | -6.988 | 450,00 | -3.144.600,00 | -189,5% | |
| 2026-05-04 | Bhatia Sangeeta N. | Director | Open Market Sale | -318 | 423,73 | -134.746,14 | -8,1% | |
| 2026-05-01 | Liu Joy | Officer, EVP and Chief Legal Officer | Open Market Sale | -1.104 | 425,02 | -469.222,08 | -28,3% | |
| 2026-04-01 | Liu Joy | Officer, EVP and Chief Legal Officer | Open Market Sale | -978 | 449,17 | -439.288,26 | -26,5% | |
| 2026-03-27 | Bozic Carmen | Officer, EVP and CMO | Open Market Sale | -2.329 | 450,95 | -1.050.262,55 | -63,3% | |
| 2026-03-13 | Bozic Carmen | Officer, EVP and CMO | Open Market Sale | -2.329 | 481,79 | -1.122.088,91 | -67,6% | |
| 2026-03-11 | McKechnie Duncan | Officer, EVP, Chief Commercial Officer | Open Market Sale | -2.633 | 498,42 | -1.312.339,86 | -79,1% | |
| 2026-03-04 | McKechnie Duncan | Officer, EVP, Chief Commercial Officer | Open Market Sale | -2.437 | 475,30 | -1.158.306,10 | -69,8% | |
| 2026-03-02 | Liu Joy | Officer, EVP and Chief Legal Officer | Open Market Sale | -892 | 495,96 | -442.396,32 | -26,7% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -2.725 | 490,54 | -1.336.721,50 | -80,5% | |
| 2026-02-27 | Bozic Carmen | Officer, EVP and CMO | Open Market Sale | -2.329 | 480,31 | -1.118.641,99 | -67,4% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -15.580 | 495,38 | -7.718.020,40 | -465,0% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -5.995 | 496,16 | -2.974.479,20 | -179,2% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -3.498 | 494,33 | -1.729.166,34 | -104,2% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -3.278 | 488,27 | -1.600.549,06 | -96,4% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -2.520 | 493,29 | -1.243.090,80 | -74,9% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -2.510 | 487,13 | -1.222.696,30 | -73,7% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -1.725 | 496,95 | -857.238,75 | -51,6% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -949 | 491,30 | -466.243,70 | -28,1% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -460 | 489,32 | -225.087,20 | -13,6% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -400 | 479,75 | -191.900,00 | -11,6% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -240 | 482,84 | -115.881,60 | -7,0% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -120 | 481,50 | -57.780,00 | -3,5% | |
| 2026-02-26 | Ambrose Kristen | Officer, SVP & Chief Accounting Officer | Open Market Sale | -357 | 483,36 | -172.559,52 | -10,4% | |
| 2026-02-25 | McKechnie Duncan | Officer, EVP, Chief Commercial Officer | Open Market Sale | -2.410 | 489,00 | -1.178.490,00 | -71,0% | |
| 2026-02-25 | Tatsis Ourania | Officer, EVP, Chief Reg. & Quality Off. | Open Market Sale | -260 | 486,35 | -126.451,00 | -7,6% | |
| 2026-02-25 | Sachdev Amit | Officer, EVP Chief Patient & Ext Af Off | Open Market Sale | -1.846 | 486,35 | -897.802,10 | -54,1% | |
| 2026-02-25 | Atkinson Edward Morrow III | Officer, EVP, Chief Technical Ops. Off. | Open Market Sale | -668 | 486,35 | -324.881,80 | -19,6% | |
| 2026-02-25 | Ambrose Kristen | Officer, SVP & Chief Accounting Officer | Open Market Sale | -223 | 486,35 | -108.456,05 | -6,5% | |
| 2026-02-25 | Biller Jonathan | Officer, EVP and Chief Legal Officer | Open Market Sale | -945 | 486,35 | -459.600,75 | -27,7% | |
| 2026-02-25 | McKechnie Duncan | Officer, EVP, Chief Commercial Officer | Open Market Sale | -2.500 | 486,35 | -1.215.875,00 | -73,3% | |
| 2026-02-25 | Bunnage Mark E. | Officer, EVP, Chief Scientific Officer | Open Market Sale | -620 | 486,35 | -301.537,00 | -18,2% | |
| 2026-02-19 | Sachdev Amit | Officer, EVP Chief Patient & Ext Af Off | Open Market Sale | -1.848 | 465,80 | -860.798,40 | -51,9% | |
| 2026-02-19 | Sachdev Amit | Officer, EVP Chief Patient & Ext Af Off | Open Market Sale | -920 | 463,91 | -426.797,20 | -25,7% | |
| 2026-02-19 | Sachdev Amit | Officer, EVP Chief Patient & Ext Af Off | Open Market Sale | -2.730 | 465,05 | -1.269.586,50 | -76,5% | |
| 2026-02-19 | Sachdev Amit | Officer, EVP Chief Patient & Ext Af Off | Open Market Sale | -4.237 | 471,43 | -1.997.448,91 | -120,3% | |
| 2026-02-19 | Sachdev Amit | Officer, EVP Chief Patient & Ext Af Off | Open Market Sale | -7.241 | 469,61 | -3.400.446,01 | -204,9% | |
| 2026-02-19 | Sachdev Amit | Officer, EVP Chief Patient & Ext Af Off | Open Market Sale | -10.263 | 467,75 | -4.800.518,25 | -289,2% | |
| 2026-02-19 | Sachdev Amit | Officer, EVP Chief Patient & Ext Af Off | Open Market Sale | -11.712 | 470,54 | -5.510.964,48 | -332,0% | |
| 2026-02-19 | Sachdev Amit | Officer, EVP Chief Patient & Ext Af Off | Open Market Sale | -19.662 | 468,57 | -9.213.023,34 | -555,1% | |
| 2026-02-18 | Bunnage Mark E. | Officer, EVP, Chief Scientific Officer | Open Market Sale | -1.182 | 473,68 | -559.889,76 | -33,7% | |
| 2026-02-18 | Atkinson Edward Morrow III | Officer, EVP, Chief Technical Ops. Off. | Open Market Sale | -817 | 473,68 | -386.996,56 | -23,3% | |
| 2026-02-18 | Tatsis Ourania | Officer, EVP, Chief Reg. & Quality Off. | Open Market Sale | -368 | 473,68 | -174.314,24 | -10,5% | |
| 2026-02-18 | Ambrose Kristen | Officer, SVP & Chief Accounting Officer | Open Market Sale | -638 | 473,68 | -302.207,84 | -18,2% | |
| 2026-02-18 | Biller Jonathan | Officer, EVP and Chief Legal Officer | Open Market Sale | -1.244 | 473,68 | -589.257,92 | -35,5% | |
| 2026-02-17 | Biller Jonathan | Officer, EVP and Chief Legal Officer | Open Market Sale | -2.476 | 489,46 | -1.211.902,96 | -73,0% | |
| 2026-02-17 | Ambrose Kristen | Officer, SVP & Chief Accounting Officer | Open Market Sale | -1.557 | 489,46 | -762.089,22 | -45,9% | |
| 2026-02-17 | Atkinson Edward Morrow III | Officer, EVP, Chief Technical Ops. Off. | Open Market Sale | -2.031 | 489,46 | -994.093,26 | -59,9% | |
| 2026-02-17 | Bunnage Mark E. | Officer, EVP, Chief Scientific Officer | Open Market Sale | -2.437 | 489,46 | -1.192.814,02 | -71,9% | |
| 2026-02-17 | Tatsis Ourania | Officer, EVP, Chief Reg. & Quality Off. | Open Market Sale | -609 | 489,46 | -298.081,14 | -18,0% | |
| 2026-02-13 | Bhatia Sangeeta N. | Director | Open Market Sale | -266 | 500,00 | -133.000,00 | -8,0% | |
| 2026-02-13 | Tatsis Ourania | Officer, EVP, Chief Reg. & Quality Off. | Open Market Sale | -1.500 | 499,99 | -749.985,00 | -45,2% | |
| 2026-02-13 | Biller Jonathan | Officer, EVP and Chief Legal Officer | Open Market Sale | -988 | 499,00 | -493.012,00 | -29,7% | |
| 2026-02-11 | Biller Jonathan | Officer, EVP and Chief Legal Officer | Open Market Sale | -1.925 | 460,43 | -886.327,75 | -53,4% | |
| 2026-02-11 | Tatsis Ourania | Officer, EVP, Chief Reg. & Quality Off. | Open Market Sale | -466 | 460,43 | -214.560,38 | -12,9% | |
| 2026-02-11 | Ambrose Kristen | Officer, SVP & Chief Accounting Officer | Open Market Sale | -1.376 | 460,43 | -633.551,68 | -38,2% | |
| 2026-02-11 | Atkinson Edward Morrow III | Officer, EVP, Chief Technical Ops. Off. | Open Market Sale | -1.751 | 460,43 | -806.212,93 | -48,6% | |
| 2026-02-11 | Bunnage Mark E. | Officer, EVP, Chief Scientific Officer | Open Market Sale | -2.021 | 460,43 | -930.529,03 | -56,1% | |
| 2026-01-07 | Tatsis Ourania | Officer, EVP, Chief Reg. & Quality Off. | Open Market Sale | -4.500 | 474,99 | -2.137.455,00 | -128,8% | |
| 2026-01-06 | WAGNER CHARLES F JR | Officer, EVP, CO & FO | Open Market Sale | -9.532 | 461,00 | -4.394.252,00 | -264,7% | |
| 2025-12-03 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -1.152 | 447,05 | -515.001,60 | -31,0% | |
| 2025-12-03 | WAGNER CHARLES F JR | Officer, EVP, CO & FO | Open Market Sale | -7.000 | 461,00 | -3.227.000,00 | -194,4% | |
| 2025-12-03 | WAGNER CHARLES F JR | Officer, EVP, CO & FO | Open Market Sale | -7.000 | 451,00 | -3.157.000,00 | -190,2% | |
| 2025-12-03 | Tatsis Ourania | Officer, EVP, Chief Reg. & Quality Off. | Open Market Sale | -4.500 | 449,99 | -2.024.955,00 | -122,0% | |
| 2025-12-03 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -15.681 | 452,20 | -7.090.948,20 | -427,2% | |
| 2025-12-03 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -10.360 | 453,34 | -4.696.602,40 | -283,0% | |
| 2025-12-03 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -7.899 | 445,56 | -3.519.478,44 | -212,0% | |
| 2025-12-03 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -5.880 | 449,84 | -2.645.059,20 | -159,4% | |
| 2025-12-03 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -5.809 | 451,20 | -2.621.020,80 | -157,9% | |
| 2025-12-03 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -4.469 | 440,40 | -1.968.147,60 | -118,6% | |
| 2025-12-03 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -4.352 | 444,36 | -1.933.854,72 | -116,5% | |
| 2025-12-03 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -2.469 | 443,21 | -1.094.285,49 | -65,9% | |
| 2025-12-03 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -2.320 | 448,78 | -1.041.169,60 | -62,7% | |
| 2025-12-03 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -2.070 | 455,22 | -942.305,40 | -56,8% | |
| 2025-12-03 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -1.320 | 441,26 | -582.463,20 | -35,1% | |
| 2025-12-03 | Biller Jonathan | Officer, EVP and Chief Legal Officer | Open Market Sale | -347 | 449,00 | -155.803,00 | -9,4% | |
| 2025-11-17 | Atkinson Edward Morrow III | Officer, EVP, Chief Technical Ops. Off. | Open Market Sale | -2.500 | 434,58 | -1.086.450,00 | -65,5% | |
| 2025-11-14 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -32.234 | 440,30 | -14.192.630,20 | -855,1% | |
| 2025-11-14 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -21.330 | 441,35 | -9.413.995,50 | -567,2% | |
| 2025-11-14 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -40 | 442,00 | -17.680,00 | -1,1% | |
| 2025-11-13 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -18.528 | 440,22 | -8.156.396,16 | -491,4% | |
| 2025-11-13 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -1.160 | 441,05 | -511.618,00 | -30,8% | |
| 2025-10-02 | Biller Jonathan | Officer, EVP and Chief Legal Officer | Open Market Sale | -694 | 404,21 | -280.521,74 | -16,9% | |
| 2025-08-27 | Bhatia Sangeeta N. | Director | Open Market Sale | -266 | 386,69 | -102.859,54 | -6,2% | |
| 2025-08-06 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Purchase | 5.710 | 389,95 | 2.226.614,50 | +134,1% | |
| 2025-08-06 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Purchase | 4.290 | 389,08 | 1.669.153,20 | +100,6% | |
| 2025-08-06 | SACHS BRUCE I | Director | Open Market Purchase | 1.634 | 389,36 | 636.214,24 | +38,3% | |
| 2025-08-06 | SACHS BRUCE I | Director | Open Market Purchase | 3.366 | 389,84 | 1.312.201,44 | +79,1% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
⚠ Vorläufige Daten: Erst 2951 von typischerweise 8401 Fonds (35 %) haben für das aktuelle 13F-Quartal eingereicht — Werte können sich in den kommenden Wochen noch deutlich ändern.
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| Capital World Investors | 25.368.124 | 0 | 25.368.124 | 11.327.759.436 | Neu | +100,0% | |
| BlackRock, Inc. | 23.969.517 | 0 | 23.969.517 | 10.703.348.322 | Neu | +100,0% | |
| Capital Research Global Investors | 21.125.964 | 0 | 21.125.964 | 9.433.408.963 | Neu | +100,0% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 16.512.810 | 0 | 16.512.810 | 7.373.630.177 | Neu | +100,0% | |
| STATE STREET CORP | 11.730.139 | 0 | 11.730.139 | 5.237.976.269 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 6.139.621 | 0 | 6.139.621 | 2.730.054.399 | Neu | +100,0% | |
| Invesco Ltd. | 5.331.554 | 0 | 5.331.554 | 2.380.752.123 | Neu | +100,0% | |
| Capital International Investors | 5.126.077 | 0 | 5.126.077 | 2.288.942.362 | Neu | +100,0% | |
| LOOMIS SAYLES & CO L P | 4.003.821 | 0 | 4.003.821 | 1.787.866.287 | Neu | +100,0% | |
| ALLIANCEBERNSTEIN L.P. | 3.910.786 | 0 | 3.910.786 | 1.772.993.941 | Neu | +100,0% | |
| WELLINGTON MANAGEMENT GROUP LLP | 3.212.589 | 0 | 3.212.589 | 1.434.549.493 | Neu | +100,0% | |
| MORGAN STANLEY | 3.188.881 | 0 | 3.188.881 | 1.423.964.743 | Neu | +100,0% | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 3.057.396 | 0 | 3.057.396 | 1.365.249.611 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 2.878.183 | 0 | 2.878.183 | 1.285.223.702 | Neu | +100,0% | |
| JENNISON ASSOCIATES LLC | 2.740.059 | 0 | 2.740.059 | 1.223.546.148 | Neu | +100,0% | |
| Clearbridge Investments, LLC | 2.700.975 | 0 | 2.700.975 | 1.206.093.269 | Neu | +100,0% | |
| AMERIPRISE FINANCIAL INC | 2.633.481 | 0 | 2.633.481 | 1.175.957.388 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 2.564.264 | 0 | 2.564.264 | 1.145.046.448 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 2.466.575 | 0 | 2.466.575 | 1.101.424.226 | Neu | +100,0% | |
| Janus Henderson Group Ltd. | 2.131.527 | 0 | 2.131.527 | 951.794.666 | Neu | +100,0% | |
| FMR LLC | 2.020.265 | 0 | 2.020.265 | 902.128.614 | Neu | +100,0% | |
| Legal & General Group Plc | 1.955.764 | 0 | 1.955.764 | 873.326.855 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.920.871 | 0 | 1.920.871 | 857.745.736 | Neu | +100,0% | |
| VICTORY CAPITAL MANAGEMENT INC | 1.888.521 | 0 | 1.888.521 | 843.328.237 | Neu | +100,0% | |
| DEUTSCHE BANK AG\ | 1.537.736 | 0 | 1.537.736 | 686.660.634 | Neu | +100,0% | |
| Amundi | 1.472.496 | 0 | 1.472.496 | 657.528.364 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.283.721 | 0 | 1.283.721 | 573.232.775 | Neu | +100,0% | |
| WCM INVESTMENT MANAGEMENT, LLC | 1.121.341 | 0 | 1.121.341 | 496.933.478 | Neu | +100,0% | |
| ROYAL BANK OF CANADA | 1.111.871 | 0 | 1.111.871 | 496.496.000 | Neu | +100,0% | |
| Nuveen, LLC | 1.084.495 | 0 | 1.084.495 | 484.270.397 | Neu | +100,0% | |
| DIMENSIONAL FUND ADVISORS LP | 989.342 | 0 | 989.342 | 441.758.953 | Neu | +100,0% | |
| EDGEWOOD MANAGEMENT LLC | 905.129 | 0 | 905.129 | 404.176.304 | Neu | +100,0% | |
| BNP Paribas Asset Management Holding S.A. | 848.047 | 0 | 848.047 | 378.713.334 | Neu | +100,0% | |
| Assenagon Asset Management S.A. | 759.564 | 537.248 | 222.316 | 377.298.226 | Aufgestockt | +41,4% | |
| AMERICAN CENTURY COMPANIES INC | 813.285 | 0 | 813.285 | 363.164.284 | Neu | +100,0% | |
| WELLS FARGO & COMPANY/MN | 744.995 | 0 | 744.995 | 332.669.307 | Neu | +100,0% | |
| Swiss National Bank | 744.600 | 0 | 744.600 | 332.493.684 | Neu | +100,0% | |
| UBS Group AG | 742.718 | 0 | 742.718 | 331.653.296 | Neu | +100,0% | |
| CITIGROUP INC | 733.107 | 0 | 733.107 | 327.361.510 | Neu | +100,0% | |
| BARCLAYS PLC | 684.963 | 0 | 684.963 | 305.863.378 | Neu | +100,0% | |
| Bellevue Group AG | 681.908 | 0 | 681.908 | 304.499.199 | Neu | +100,0% | |
| HSBC HOLDINGS PLC | 667.943 | 0 | 667.943 | 298.242.420 | Neu | +100,0% | |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 638.950 | 0 | 638.950 | 285.316.733 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 631.498 | 0 | 631.498 | 281.989.117 | Neu | +100,0% | |
| Sumitomo Mitsui Trust Group, Inc. | 614.448 | 0 | 614.448 | 274.375.610 | Neu | +100,0% | |
| Mitsubishi UFJ Asset Management Co., Ltd. | 597.497 | 0 | 597.497 | 266.806.310 | Neu | +100,0% | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 553.243 | 0 | 553.243 | 247.045.129 | Neu | +100,0% | |
| Neuberger Berman Group LLC | 551.522 | 0 | 551.522 | 246.341.499 | Neu | +100,0% | |
| FRANKLIN RESOURCES INC | 551.132 | 0 | 551.132 | 246.102.484 | Neu | +100,0% | |
| National Pension Service | 532.069 | 0 | 532.069 | 237.590.091 | Neu | +100,0% |
Top-Fondshalter (Stand: 30.06.2026) ⓘ
⚠ Vorläufige Daten: Erst 2951 von typischerweise 8401 Fonds (35 %) haben für dieses Quartal eingereicht. Vollständigkeit erwartet bis 14.08.2026. Auswertungen (NEW/INC/DEC) sind noch zu konservativ — viele Spätfiler erscheinen aktuell als „Exits".
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) | Stimmkontrolle | Verlauf |
|---|---|---|---|---|---|---|---|
| Assenagon Asset Management S.A. | 759.564 | 537.248 | +41,4% | 377.298.226 | 12,74 | 100 % | 17 Q |
| Robeco Institutional Asset Management B.V. | 404.396 | 401.644 | +0,7% | 200.875.624 | 6,78 | 39 % | 17 Q |
| Swedbank AB | 282.444 | 271.553 | +4,0% | 140.298.409 | 4,74 | 100 % | 15 Q |
| Mirae Asset Global Investments Co., Ltd. | 210.209 | 188.064 | +11,8% | 104.417.116 | 3,53 | 100 % | 17 Q |
| DAVENPORT & Co LLC | 207.108 | 210.152 | -1,4% | 103.026.018 | 3,48 | 95 % | 17 Q |
| FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND | 148.682 | 149.962 | -0,9% | 73.854.811 | 2,49 | 100 % | 16 Q |
| Birch Hill Investment Advisors LLC | 147.702 | 150.795 | -2,1% | 73.368.014 | 2,48 | 100 % | 17 Q |
| Asset Management One Co., Ltd. | 139.597 | 141.949 | -1,7% | 69.342.018 | 2,34 | 100 % | 17 Q |
| Banco Santander, S.A. | 108.075 | 99.388 | +8,7% | 53.684.095 | 1,81 | 100 % | 14 Q |
| TRUIST FINANCIAL CORP | 106.967 | 114.449 | -6,5% | 53.133.547 | 1,79 | 51 % | 17 Q |
| COUNTRY TRUST BANK | 100.360 | 105.075 | -4,5% | 49.851.823 | 1,68 | 100 % | 17 Q |
| Swiss Life Asset Management Ltd | 91.614 | 82.574 | +10,9% | 45.507.422 | 1,54 | 100 % | 17 Q |
| ABN AMRO INVESTMENT SOLUTIONS | 84.631 | 68.216 | +24,1% | 42.038.756 | 1,42 | 100 % | 14 Q |
| Resona Asset Management Co.,Ltd. | 84.092 | 90.312 | -6,9% | 41.817.517 | 1,41 | 100 % | 10 Q |
| Eurizon Capital SGR S.p.A. | 82.582 | 81.509 | +1,3% | 41.034.984 | 1,39 | 95 % | 3 Q |
| Erste Asset Management GmbH | 76.558 | 91.958 | -16,7% | 38.205.018 | 1,29 | 99 % | 17 Q |
| Czech National Bank | 72.243 | 69.176 | +4,4% | 35.885.265 | 1,21 | 100 % | 16 Q |
| GATEWAY INVESTMENT ADVISERS LLC | 67.289 | 67.121 | +0,3% | 33.424.465 | 1,13 | 100 % | 17 Q |
| Apollon Wealth Management, LLC | 63.910 | 38.595 | +65,6% | 31.746.022 | 1,07 | 18 % | 17 Q |
| Sumitomo Mitsui DS Asset Management Company, Ltd | 63.330 | 63.822 | -0,8% | 31.457.911 | 1,06 | 100 % | 17 Q |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 30.06.2026 | vorl. | 625 | 6,8 | 2.994 |
| 31.03.2026 | ✓ | 1.661 | 258,5 | 112.981 |
| 31.12.2025 | ✓ | 1.629 | 246,4 | 108.659 |
| 30.09.2025 | ✓ | 1.508 | 245,2 | 93.074 |
| 30.06.2025 | ✓ | 1.531 | 244,8 | 104.507 |
| 31.03.2025 | ✓ | 1.572 | 250,9 | 114.207 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) |
|---|---|---|
| D. E. Shaw & Co., Inc. | 248.960 | 111.170.598 |
| SEB Asset Management AB | 140.951 | 62.940.209 |
| Tri Locum Partners LP | 129.314 | 57.743.874 |
| CAPITAL FUND MANAGEMENT S.A. | 122.934 | 54.894.948 |
| Jones Hill Capital LP | 108.603 | 48.495.584 |
| CIBC Bancorp USA Inc. | 63.952 | 28.564.199 |
| NATIXIS | 48.192 | 21.519.656 |
| Integral Health Asset Management, LLC | 40.000 | 17.861.600 |
| CAXTON ASSOCIATES LLP | 36.026 | 16.087.050 |
| Y-Intercept (Hong Kong) Ltd | 35.829 | 15.999.082 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| Capital Research Global Investors | 21.125.964 | 3.809.620 | +22.0 % | 9.433.408.963 |
| GOLDMAN SACHS GROUP INC | 2.417.875 | 663.757 | +37.8 % | 1.079.677.728 |
| Capital International Investors | 5.126.077 | 392.481 | +8.3 % | 2.288.942.362 |
| TWO SIGMA INVESTMENTS, LP | 378.146 | 373.991 | +9001.0 % | 168.857.315 |
| BlackRock, Inc. | 23.969.517 | 217.528 | +0.9 % | 10.703.348.322 |
| AGF MANAGEMENT LTD | 201.403 | 200.835 | +35358.3 % | 89.934.496 |
| JONES FINANCIAL COMPANIES LLLP | 202.860 | 194.865 | +2437.3 % | 87.854.830 |
| BNP Paribas Asset Management Holding S.A. | 848.047 | 178.240 | +26.6 % | 378.713.334 |
| Amundi | 1.472.496 | 168.335 | +12.9 % | 657.528.364 |
| AMF Tjanstepension AB | 312.917 | 166.968 | +114.4 % | 139.729.957 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| VICTORY CAPITAL MANAGEMENT INC | 1.888.521 | -1.468.245 | -43.7 % | 843.328.237 |
| WELLINGTON MANAGEMENT GROUP LLP | 3.212.589 | -609.142 | -15.9 % | 1.434.549.493 |
| ALLIANCEBERNSTEIN L.P. | 3.910.786 | -585.696 | -13.0 % | 1.772.993.941 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.760.122 | -518.836 | -22.8 % | 785.966 |
| JENNISON ASSOCIATES LLC | 2.740.059 | -509.482 | -15.7 % | 1.223.546.148 |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | 364.513 | -439.260 | -54.6 % | 162.769.066 |
| NORDEA INVESTMENT MANAGEMENT AB | 27.171 | -419.998 | -93.9 % | 12.040.557 |
| Pictet Asset Management Holding SA | 337.569 | -414.856 | -55.1 % | 150.085.600 |
| Squarepoint Ops LLC | 6.752 | -382.268 | -98.3 % | 3.015.038 |
| Invesco Ltd. | 5.331.554 | -368.507 | -6.5 % | 2.380.752.123 |
Zusätzlich aktuell von 400 Mutual Funds/ETFs gehalten (N-PORT). Alle Fondsgesellschaften & ihre 4-Quartals-Bewegungen →
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Δ-Balken |
|---|---|---|---|---|---|---|
| 14.05.2026 | Capital World Investors | Passiv (13G/A) | 10,10 % | 25.695.015 | -1,10 pp | |
| 14.05.2026 | Capital Research Global Investors | Passiv (13G/A) | 8,30 % | 21.139.169 | +1,50 pp | |
| 30.04.2026 | Vanguard Capital Management | Passiv (13G) | 7,49 % | 19.036.076 | Neu | |
| 27.03.2026 | The Vanguard Group | Passiv (13G/A) | Ausstieg | 0 | -8,65 pp | |
| 12.02.2026 | Capital Research Global Investors | Passiv (13G/A) | 6,80 % | 17.319.044 | +1,10 pp | |
| 13.05.2025 | Capital Research Global Investors | Passiv (13G) | 5,70 % | 14.536.344 | Neu | |
| 13.02.2025 | Capital World Investors | Passiv (13G/A) | 11,20 % | 28.739.975 | +1,20 pp | |
| 12.02.2025 | Abigail P. Johnson (+1) | Passiv (13G/A) | 3,60 % | 9.220.827 | Neu | |
| 10.04.2024 | Capital World Investors | Passiv (13G/A) | 10,00 % | 25.902.938 | +1,40 pp | |
| 13.02.2024 | The Vanguard Group | Passiv (13G/A) | 8,65 % | 22.281.729 | +0,26 pp | |
| 09.02.2024 | Capital World Investors | Passiv (13G/A) | 8,60 % | 22.080.207 | +3,60 pp | |
| 25.01.2024 | . BlackRock, Inc. | Passiv (13G) | 8,50 % | 21.881.203 | -0,90 pp | |
| 13.02.2023 | Capital World Investors | Passiv (13G) | 5,00 % | 12.939.319 | Neu | |
| 09.02.2023 | The Vanguard Group | Passiv (13G/A) | 8,39 % | 21.546.903 | +0,46 pp | |
| 24.01.2023 | . BlackRock, Inc. | Passiv (13G) | 9,40 % | 24.241.437 | 0,00 pp | |
| 14.02.2022 | T. ROWE PRICE ASSOCIATES, INC. | Passiv (13G/A) | 2,10 % | 5.421.291 | -5,40 pp | |
| 10.02.2022 | The Vanguard Group | Passiv (13G/A) | 7,93 % | 20.155.842 | +0,07 pp | |
| 01.02.2022 | . BlackRock, Inc. | Passiv (13G/A) | 9,40 % | 23.944.931 | +0,10 pp |
US Congress Trades (STOCK Act)
| Datum | Mitglied | Partei | Kammer | Typ | Betrag-Bereich |
|---|---|---|---|---|---|
| 27.03.2026 | Alan Armstrong | – | Senate | Kauf | $1,001 – $15,000 |
| 29.01.2026 | David J Taylor | – | House | Verkauf | $1,001 – $15,000 |
| 07.08.2025 | David J Taylor | – | House | Kauf | $1,001 – $15,000 |
| 11.06.2025 | Lisa McClain | – | House | Verkauf | $1,001 – $15,000 |
| 12.05.2025 | Jefferson Shreve | – | House | Verkauf | $15,001 – $50,000 |
| 20.03.2025 | Byron Donalds | – | House | Verkauf | $1,001 – $15,000 |
| 20.03.2025 | Byron Donalds | – | House | Verkauf | $1,001 – $15,000 |
| 13.03.2025 | Jefferson Shreve | – | House | Kauf | $15,001 – $50,000 |
| 24.02.2025 | Jefferson Shreve | – | House | Kauf | $15,001 – $50,000 |
| 11.12.2024 | Lisa McClain | – | House | Kauf | $1,001 – $15,000 |
| 23.10.2024 | Julia Letlow | – | House | Kauf | $1,001 – $15,000 |
Quelle: House eFD & Senate eFD (STOCK Act PTR). Betragsangaben sind Bereichsangaben — keine Exaktwerte. Tiefenanalyse für diese Aktie → · Alle Kongress-Bestände →
Finanzkennzahlen (SEC XBRL) ⓘ
Währung:
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | – | 1.031.400.000 $ | 4,02 $ | 26.484.400.000 $ | 19.361.900.000 $ |
| 2025-12-31 | 10-K | – | 3.953.200.000 $ | 15,32 $ | 25.643.000.000 $ | 18.665.800.000 $ |
| 2025-09-30 | 10-Q | – | 1.082.900.000 $ | 4,20 $ | 24.862.300.000 $ | 17.318.800.000 $ |
| 2025-06-30 | 10-Q | – | 1.032.900.000 $ | 3,99 $ | 24.036.700.000 $ | 17.175.400.000 $ |
| 2025-03-31 | 10-Q | – | 646.300.000 $ | 2,49 $ | 22.880.500.000 $ | 16.496.300.000 $ |
| 2024-12-31 | 10-K | – | -535.600.000 $ | -2,08 $ | 22.533.200.000 $ | 16.409.600.000 $ |
| 2024-09-30 | 10-Q | – | 1.045.400.000 $ | 4,01 $ | 22.240.200.000 $ | 15.630.900.000 $ |
| 2024-06-30 | 10-Q | – | -3.593.600.000 $ | -13,92 $ | 20.132.100.000 $ | 14.774.700.000 $ |
| 2024-03-31 | 10-Q | – | 1.099.600.000 $ | 4,21 $ | 23.917.400.000 $ | 18.546.600.000 $ |
| 2023-12-31 | 10-K | – | 3.619.600.000 $ | 13,89 $ | 22.730.200.000 $ | 17.580.400.000 $ |
| 2023-09-30 | 10-Q | – | 1.035.300.000 $ | 3,97 $ | 21.726.200.000 $ | 16.512.800.000 $ |
| 2023-06-30 | 10-Q | – | 915.700.000 $ | 3,52 $ | 20.349.200.000 $ | 15.470.200.000 $ |
| 2023-03-31 | 10-Q | – | 699.800.000 $ | 2,69 $ | 18.974.200.000 $ | 14.432.300.000 $ |
| 2022-12-31 | 10-K | – | 3.322.000.000 $ | 12,82 $ | 18.150.900.000 $ | 13.912.700.000 $ |
| 2022-09-30 | 10-Q | – | 930.500.000 $ | 3,59 $ | 16.706.400.000 $ | 13.029.600.000 $ |
| 2022-06-30 | 10-Q | – | 810.500.000 $ | 3,13 $ | 15.582.200.000 $ | 11.933.500.000 $ |
| 2022-03-31 | 10-Q | – | 762.100.000 $ | 2,96 $ | 14.256.100.000 $ | 10.907.000.000 $ |
| 2021-12-31 | 10-K | – | 2.342.100.000 $ | 9,01 $ | 13.432.500.000 $ | 10.100.000.000 $ |
| 2021-09-30 | 10-Q | – | 851.900.000 $ | 3,28 $ | 12.618.745.000 $ | 9.530.800.000 $ |
| 2021-06-30 | 10-Q | – | 67.000.000 $ | 0,26 $ | 12.221.686.000 $ | 9.196.400.000 $ |
Umsatz nach Segmenten & Regionen ⓘ
Geschäftssegmente
| Segment | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| Product | 12,0 Mrd. | – | 9,9 Mrd. | 8,9 Mrd. | 7,6 Mrd. | 99,7 % | Neu | |
| TRIKAFTAKAFTRIO | 10,3 Mrd. | 10,2 Mrd. | 8,9 Mrd. | 7,7 Mrd. | 5,7 Mrd. | 85,9 % | +0,7% | |
| ALYFTREK | 837,8 Mio. | – | – | – | – | 7,0 % | Neu | |
| Manufactured Product Other | 820,1 Mio. | 781,5 Mio. | – | – | – | 6,8 % | +4,9% | |
| CASGEVY | 115,8 Mio. | 10,0 Mio. | – | – | – | 1,0 % | +1058,0% | |
| JOURNAVX | 59,6 Mio. | – | – | – | – | 0,5 % | Neu | |
| Collaborativeand Royalty | 30,7 Mio. | – | – | – | 1,0 Mio. | 0,3 % | Neu | |
| Kalydeco | – | – | 475,5 Mio. | 553,2 Mio. | 684,2 Mio. | – | – | |
| ORKAMBI | – | – | 326,0 Mio. | 510,7 Mio. | 771,6 Mio. | – | – | |
| SYMDEKOSYMKEVI | – | – | 123,0 Mio. | 180,0 Mio. | 420,4 Mio. | – | – |
Quartalsverlauf
| Segment | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q3 FY2024 | Q2 FY2024 | Q1 FY2024 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Product | 3,1 Mrd. | 2,9 Mrd. | 2,8 Mrd. | – | – | – | 100,0 % | Neu | |
| TRIKAFTAKAFTRIO | 2,7 Mrd. | 2,6 Mrd. | 2,5 Mrd. | 2,6 Mrd. | 2,4 Mrd. | 2,5 Mrd. | 86,3 % | +2,7% | |
| ALYFTREK | 247,0 Mio. | 156,8 Mio. | 53,9 Mio. | – | – | – | 8,0 % | Neu | |
| Manufactured Product Other | 175,8 Mio. | 236,1 Mio. | 170,8 Mio. | 186,9 Mio. | – | – | 5,7 % | -5,9% | |
| JOURNAVX | 19,6 Mio. | 12,0 Mio. | – | – | – | – | 0,6 % | Neu | |
| CASGEVY | 16,9 Mio. | 30,4 Mio. | – | 2,0 Mio. | – | – | 0,5 % | +745,0% | |
| Collaborativeand Royalty | – | 20,7 Mio. | 10,0 Mio. | – | – | – | – | – | |
| CASGEVYAnd JOURNAVX | – | – | 14,2 Mio. | – | – | – | – | – | |
| Other Cystic Fibrosis Products | – | – | – | – | 196,4 Mio. | 207,0 Mio. | – | – |
Regionen
| Region | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| US | 7,5 Mrd. | 6,7 Mrd. | 6,0 Mrd. | 5,7 Mrd. | 4,8 Mrd. | 62,9 % | +12,9% | |
| Outsidethe United States | 4,5 Mrd. | 4,3 Mrd. | 3,8 Mrd. | 3,2 Mrd. | 1,4 Mrd. | 37,1 % | +2,7% | |
| Europe | 3,5 Mrd. | 3,5 Mrd. | 3,1 Mrd. | 2,7 Mrd. | 1,1 Mrd. | 28,8 % | +0,2% | |
| Other Countries Outsideofthe United Statesand Europe | 992,4 Mio. | 881,3 Mio. | 719,8 Mio. | 525,9 Mio. | 249,9 Mio. | 8,3 % | +12,6% |
Quartalsverlauf
| Region | Q3 FY2024 | Q2 FY2024 | Q1 FY2024 | Q3 FY2023 | Q2 FY2023 | Q1 FY2023 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|---|
| US | 1,7 Mrd. | 1,6 Mrd. | 1,5 Mrd. | 1,6 Mrd. | 1,5 Mrd. | 1,4 Mrd. | 61,8 % | +10,2% | |
| Non Us | 1,1 Mrd. | 1,0 Mrd. | 1,2 Mrd. | 929,3 Mio. | 985,4 Mio. | 971,0 Mio. | 38,2 % | +13,9% | |
| Europe | 847,7 Mio. | 806,8 Mio. | 967,4 Mio. | 766,5 Mio. | 800,0 Mio. | 807,2 Mio. | 30,6 % | +10,6% | |
| Other Non U.S. | 210,7 Mio. | 224,5 Mio. | 203,3 Mio. | 162,8 Mio. | 185,4 Mio. | 163,8 Mio. | 7,6 % | +29,4% |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 05.05.2026 | 3,0 Mrd. USD | 4,02 |
| Q3 2025 | 30.09.2025 | 04.11.2025 | 3,1 Mrd. USD | 4,20 |
| Q2 2025 | 30.06.2025 | 05.08.2025 | 3,0 Mrd. USD | 3,99 |
| Q1 2025 | 31.03.2025 | 06.05.2025 | 2,8 Mrd. USD | 2,49 |
| Q3 2024 | 30.09.2024 | 05.11.2024 | 2,8 Mrd. USD | 4,01 |
| Q2 2024 | 30.06.2024 | 02.08.2024 | 2,6 Mrd. USD | -13,92 |
| Q1 2024 | 31.03.2024 | 07.05.2024 | 2,7 Mrd. USD | 4,21 |
| Q3 2023 | 30.09.2023 | 07.11.2023 | 2,5 Mrd. USD | 3,97 |
| Q2 2023 | 30.06.2023 | 02.08.2023 | 2,5 Mrd. USD | 3,52 |
Einreichungs-Historie (10-K / 10-Q / 20-F / 6-K)
SEC-Einreichungs-Historie der letzten sechs Jahre (Datum = US-Kalendertag,
SEC/ET): Quartalsberichte (10-Q) und Jahresberichte (10-K); ausländische
Emittenten (ADR/Foreign Private Issuer) reichen stattdessen Jahresberichte
(20-F/40-F) und Zwischenmitteilungen (6-K) ein — dort liegt im SEC-Index
keine Berichtsperiode vor, Periode und Verzögerung bleiben leer. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht (US) | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 05.05.2026 | 10-Q | 31.03.2026 | 35 Tage | SEC » |
| 13.02.2026 | 10-K | 31.12.2025 | 44 Tage | SEC » |
| 04.11.2025 | 10-Q | 30.09.2025 | 35 Tage | SEC » |
| 05.08.2025 | 10-Q | 30.06.2025 | 36 Tage | SEC » |
| 06.05.2025 | 10-Q | 31.03.2025 | 36 Tage | SEC » |
| 13.02.2025 | 10-K | 31.12.2024 | 44 Tage | SEC » |
| 05.11.2024 | 10-Q | 30.09.2024 | 36 Tage | SEC » |
| 02.08.2024 | 10-Q | 30.06.2024 | 33 Tage | SEC » |
| 07.05.2024 | 10-Q | 31.03.2024 | 37 Tage | SEC » |
| 15.02.2024 | 10-K | 31.12.2023 | 46 Tage | SEC » |
| 07.11.2023 | 10-Q | 30.09.2023 | 38 Tage | SEC » |
| 02.08.2023 | 10-Q | 30.06.2023 | 33 Tage | SEC » |
| 02.05.2023 | 10-Q | 31.03.2023 | 32 Tage | SEC » |
| 10.02.2023 | 10-K | 31.12.2022 | 41 Tage | SEC » |
| 28.10.2022 | 10-Q | 30.09.2022 | 28 Tage | SEC » |
| 05.08.2022 | 10-Q | 30.06.2022 | 36 Tage | SEC » |
| 06.05.2022 | 10-Q | 31.03.2022 | 36 Tage | SEC » |
| 09.02.2022 | 10-K | 31.12.2021 | 40 Tage | SEC » |
| 03.11.2021 | 10-Q | 30.09.2021 | 34 Tage | SEC » |
| 30.07.2021 | 10-Q | 30.06.2021 | 30 Tage | SEC » |
| 30.04.2021 | 10-Q | 31.03.2021 | 30 Tage | SEC » |
| 11.02.2021 | 10-K | 31.12.2020 | 42 Tage | SEC » |
| 30.10.2020 | 10-Q | 30.09.2020 | 30 Tage | SEC » |
| 31.07.2020 | 10-Q | 30.06.2020 | 31 Tage | SEC » |
Proxy-/Governance-Filings
Proxy-Statements (SEC DEF-14A-Familie) der letzten sechs Jahre: reguläre HV-Einladungen zur Aktionärsversammlung, Aktivisten-Proxy-Fights (contested / Non-Management-Solicitation) und M&A-Abstimmungen.
| Datum (US) | Kategorie | HV-Termin (US) | Stichtag (US) | Form | |
|---|---|---|---|---|---|
| 29.04.2026 | HV-Einladung | — | — | DEFA14A | SEC » |
| 02.04.2026 | HV-Einladung | — | — | DEFA14A | SEC » |
| 02.04.2026 | HV-Einladung | 13.05.2026 Jahres-HV | 16.03.2026 | DEF 14A | SEC » |
| 03.04.2025 | HV-Einladung | — | — | DEFA14A | SEC » |
| 03.04.2025 | HV-Einladung | 14.05.2025 Jahres-HV | 17.03.2025 | DEF 14A | SEC » |
| 04.04.2024 | HV-Einladung | — | — | DEFA14A | SEC » |
| 04.04.2024 | HV-Einladung | 15.05.2024 Jahres-HV | 18.03.2024 | DEF 14A | SEC » |
| 06.04.2023 | HV-Einladung | — | — | DEFA14A | SEC » |
| 06.04.2023 | HV-Einladung | — | — | DEF 14A | SEC » |
| 07.04.2022 | HV-Einladung | — | — | DEFA14A | SEC » |
| 07.04.2022 | HV-Einladung | 18.05.2022 Jahres-HV | 24.03.2022 | DEF 14A | SEC » |
| 08.04.2021 | HV-Einladung | — | — | DEFA14A | SEC » |
| 08.04.2021 | HV-Einladung | 19.05.2021 Jahres-HV | 25.03.2021 | DEF 14A | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). HV-Termin = Datum der Aktionärsversammlung, Stichtag (Record Date) = Nachweisstichtag für die Stimmberechtigung (aus dem Dokument extrahiert).
Übernahmen & Fusionen (M&A)
M&A-relevante SEC-Filings der letzten sechs Jahre: Übernahmeangebote (Tender Offers), Fusionen (425/S-4), Aktienrückkauf-Angebote (Self-Tender) und Going-Private-Transaktionen. Geführt nach dem einreichenden Emittenten.
| Datum (US) | Kategorie | Form | Deal-Konditionen | SEC |
|---|---|---|---|---|
| 20.05.2024 | Übernahmeangebot | SC TO-T/A | – | SEC » |
| 10.05.2024 | Übernahmeangebot | SC TO-T/A | – | SEC » |
| 08.05.2024 | Übernahmeangebot | SC TO-T/A | – | SEC » |
| 22.04.2024 | Übernahmeangebot | SC TO-T | $65,00 Cash | SEC » |
| 11.04.2024 | Übernahmeangebot | SC TO-C | – | SEC » |
| 11.04.2024 | Übernahmeangebot | SC TO-C | – | SEC » |
| 10.04.2024 | Übernahmeangebot | SC TO-C | – | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Deal-Konditionen aus dem Dokument extrahiert (Tender: SC TO-T/-I/SC 14D9; Fusion: 425/S-4 — Gegenpartei + Umtauschverhältnis), ohne Gewähr — Original siehe SEC-Link.
Filing-Analyse (10-K / 10-Q)
Narrative-Analyse der letzten Quartals-/Jahresberichte durch Claude (nur Coverage-Gruppen-Mitglieder). Keine Anlageberatung — der qualitative Score dient der Einordnung, nicht als Kaufempfehlung; siehe allgemeiner Hinweis am Seitenende.
🔒 Die aufklappbare Detailanalyse (Red Flags, Risiko-Änderungen, Guidance-Zitate, voller Wortlaut) ist Teil des Kunden-Abos — freischalten.
| Datum | Form | Stimmung | Guidance | Risiko-Δ | Qualitativ | Zusammenfassung | |
|---|---|---|---|---|---|---|---|
| 13.02.2026 | 10-K | 0,48 | ↑ | 0,00 | 70 | Vertex erzielte 2025 einen Umsatz von 12,0 Mrd. USD (+9 %) getragen von starker TRIKAFTA/KAFTRIO-Nachfrage und den erfolgreichen Launches von ALYFTREK, JOURNAVX und CASGEVY bei einer komfortablen Liquidität von 12,3 Mrd. USD und einem operativen Cas… | 🔒 |
Kritische 8-K Meldungen ⓘ
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (13.05.2026)
HOCH Abgang Schlüsselpersonen (13.05.2026)
| Datum | Meldung | Tags | Schwere | Filing | Auszug |
|---|---|---|---|---|---|
| 13.05.2026 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors of Directors or Certain Officers; Election of Directors; Appointment of Certain… |
| 29.04.2026 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors… |
| 04.08.2025 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 10.02.2025 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 05.12.2023 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Section 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors… |
| 05.10.2023 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Section 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors… |
| 01.04.2020 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
8-K-Ereignisse (KI)
🔒 Die vollständige KI-Einordnung je 8-K ist Teil des Kunden-Abos — freischalten.
| Datum | Ereignis | Sentiment | Materialität | Zusammenfassung | Filing |
|---|---|---|---|---|---|
| 07.07.2026 | Sonstiges | 0,00 | 35 | Vertex Pharmaceuticals und seine Elternsocietät haben am 6. Juli 2026 eine gemeinsame Erklärung veröffentlicht. | SEC |
| 13.05.2026 | Personalwechsel | 0,00 | 20 | Genehmigung eines neuen 2026 Stock and Option Plans am 27.03.2026 zur Ersetzung des 2013-Plans, vorbehaltlich Aktionärsbestätigung. | SEC |
| 04.05.2026 | Quartalszahlen | 0,00 | 55 | Vertex Pharmaceuticals meldet Finanzergebnisse für Q1 2026 (endet 31. März 2026) per Press Release am 4. Mai 2026. | SEC |
| 29.04.2026 | Personalwechsel | -0,05 | 20 | Der Direktor Suketu Upadhyay wird sich bei der Jahreshauptversammlung 2026 nicht zur Wiederwahl stellen. | SEC |
| 31.03.2026 | Behördliche Maßnahme | 0,70 | 70 | Vertex Pharmaceuticals hat eine Biologics Licensing Application für Povetacicept zur Behandlung von IgA-Nephropathie eingereicht. Mit Priori… 🔒 | SEC |
| 12.02.2026 | Quartalszahlen | 0,00 | 70 | Vertex Pharmaceuticals veröffentlichte am 12. Februar 2026 die konsolidierten Finanzergebnisse für das vierte Quartal und das Geschäftsjahr … 🔒 | SEC |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-06-29 | 24 | 491,34 | 11.792 |
| 2026-06-25 | 3.775 | 475,20 | 1.793.880 |
| 2026-06-15 | 3.554 | 444,93 | 1.581.281 |
| 2026-06-12 | 1.170 | 445,04 | 520.697 |
| 2026-06-09 | 1 | 442,96 | 443 |
| 2026-06-08 | 47 | 446,83 | 21.001 |
| 2026-06-02 | 601 | 438,40 | 263.478 |
| 2026-05-07 | 1 | 427,65 | 428 |
| 2026-05-06 | 214 | 424,36 | 90.813 |
| 2026-05-04 | 14 | 423,92 | 5.935 |
| 2026-04-24 | 1.290 | 435,10 | 561.279 |
| 2026-04-23 | 1 | 437,67 | 438 |
| 2026-04-16 | 2.143 | 441,70 | 946.563 |
| 2026-04-15 | 14 | 444,28 | 6.220 |
| 2026-04-08 | 1 | 431,86 | 432 |
| 2026-03-30 | 42.186 | 433,07 | 18.269.491 |
| 2026-03-25 | 5.705 | 448,62 | 2.559.377 |
| 2026-03-23 | 2.095 | 454,00 | 951.130 |
| 2026-03-17 | 40.515 | 466,10 | 18.884.042 |
| 2026-03-13 | 341 | 478,13 | 163.042 |
| 2026-02-25 | 300 | 487,43 | 146.229 |
| 2026-02-24 | 300 | 481,01 | 144.303 |
| 2026-02-20 | 1.216 | 469,27 | 570.632 |
| 2026-02-18 | 72 | 477,32 | 34.367 |
| 2026-02-17 | 14.013 | 491,47 | 6.886.969 |
| 2026-02-13 | 300 | 465,02 | 139.506 |
| 2026-02-12 | 3.833 | 461,24 | 1.767.933 |
| 2026-02-09 | 2.800 | 477,92 | 1.338.176 |
| 2026-02-04 | 915 | 465,61 | 426.033 |
| 2026-02-02 | 200 | 469,90 | 93.980 |